Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev. 2009 Jul;(3):CD006324.

Elizagarate E, Sánchez P, Ezcurra J. (Eds). (2011), La esquizofrenia refractaria. Vitoria-Gasteiz: Ikusager Ediciones. ISBN: 978-84-89213-21-0.

Farooq S, Taylor M. Clozapine: dangerous orphan or neglected friend? Br J Psychiatry. 2011 Apr;198:247-9.

Grande I, Pons A, Baeza I, Torras Á, Bernardo M. QTc prolongation: is clozapine safe? Study of 82 cases before and after clozapine treatment. Hum Psychopharmacol. 2011 Aug;26(6):397-403.

Girgis RR, Phillips MR, Li X, Li K, Jiang H, Wu C, Duan N, Niu Y, Lieberman JA. Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. Br J Psychiatry. 2011 Oct;199:281-8.

Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988 Sep;45(9):789-96.

Kilian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine.Lancet. 1999 Nov;354(9193):1841-5.

Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009 Jan;373(9657):31-41.

Pedrini M, Chendo I, Grande I, Lobato MI, Belmonte-de-Abreu PS, Lersch C, Walz J, Kauer-Sant’anna M, Kapczinski F, Gama CS. Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: a positive correlation. Neurosci Lett. 2011 Mar;491(3):207-10.

Rothschild AJ (Ed). (2010), The Evidence-Based Guide to Antipsychotic medications. Washington DC; American Psychiatric Publishing.

Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009 Aug;374(9690):620-7.

Gören JL, Rose AJ, Smith EG, Ney JP, The Business Case for Expanded Clozapine Utilization. Psychiatr Serv. 2016 Nov;67(11):1197-1205.

Gören JL, Rose AJ, Engle RL, Smith EG, Christopher ML, Rickles NM, Semla TP, McCullough MB, Organizational Characteristics of Veterans Affairs Clinics With High and Low Utilization of Clozapine. Psychiatr Serv. 2016 Nov;67(11):1189-1196.

Nielsen J, Correll CU, Manu P, Kane JM, Termination of Clozapine Treatment Due to Medical Reasons: When Is It Warranted and How Can It Be Avoided? J Clin Psychiatry. 2013 Jun;74(6):603–613

Carruthers J, Radigan M, Erlich MD, Gu G, Wang R, Frimpong EY, Essock SM, Olfson M, Castillo EG, Miller GA, Sederer LI, Stroup TS, An Initiative to Improve Clozapine Prescribing in New York State. Psychiatric Serv.ices 2016 Apr; 67(4):369–371.

Tungaraza TE, Farooq S, Clozapine prescribing in the UK: views and experience of consultant psychiatrists. Ther Adv in Psychopharmacol 2015 Apr; 5 (2): 88–96.